- Datum04.11.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Adverum Biotechnologies Inc. Aktie
Verkaufen
Kaufen
Adverum Biotechnologies Inc. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Adverum Biotechnologies Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Stuttgart | VK | |||||
| Baader | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
3,12 %
Intraday
-2,32 %
1 Woche
3,87 %
1 Monat
-36,83 %
Seit Jahresbeginn
-60,67 %
1 Jahr
-72,04 %
3 Jahre
-97,62 %
5 Jahre
Passender Service zu Adverum Biotechnologies Inc.
Webinar zu Adverum Biotechnologies Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,780-8,560
- Jahrestief / Hoch ($)1,780-5,724
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Adverum Biotechnologies Inc.
Keine Dividenden verfügbar
Termine von Adverum Biotechnologies Inc.
Keine aktuellen Termine
Beschreibung
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
